| How does use of a prescription monitoring program change medical practice? TC Green, MR Mann, SE Bowman, N Zaller, X Soto, J Gadea, C Cordy, ... Pain Medicine 13 (10), 1314-1323, 2012 | 100 | 2012 |
| Cost utility of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease M Zimmermann, SJ Lubinga, R Banken, D Rind, G Cramer, PG Synnott, ... Value in Health 22 (2), 161-167, 2019 | 64 | 2019 |
| Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis M Sonya Kahn, D Rind, R Chapman, V Kumar, S Kahn, J Carlson J Drugs Dermatol 17 (7), 750-756, 2018 | 59 | 2018 |
| Disease-modifying therapies for relapsing–remitting and primary progressive multiple sclerosis: a cost-utility analysis M Zimmermann, E Brouwer, JA Tice, M Seidner, AM Loos, S Liu, ... CNS drugs 32, 1145-1157, 2018 | 50 | 2018 |
| How does use of a prescription monitoring program change pharmacy practice? TC Green, MR Mann, SE Bowman, N Zaller, X Soto, J Gadea Jr, C Cordy, ... Journal of the American Pharmacists Association 53 (3), 273-281, 2013 | 50 | 2013 |
| Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems RJ Duintjer Tebbens, M Zimmermann, MA Pallansch, KM Thompson Food and environmental virology 9 (4), 361-382, 2017 | 43 | 2017 |
| Life after the ban: an assessment of US syringe exchange programs’ attitudes about and early experiences with federal funding TC Green, EG Martin, SE Bowman, MR Mann, L Beletsky American Journal of Public Health 102 (5), e9-e16, 2012 | 41 | 2012 |
| Costs of integrating cervical cancer screening at an HIV clinic in Kenya EL Vodicka, JB Babigumira, MR Mann, RJ Kosgei, F Lee, NR Mugo, ... International Journal of Gynecology & Obstetrics 136 (2), 220-228, 2017 | 29 | 2017 |
| Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups T Cloppenborg, M Stanulla, M Zimmermann, M Schrappe, K Welte, ... Leukemia 19 (1), 44-48, 2005 | 29 | 2005 |
| Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure M Mann, L Diero, E Kemboi, F Mambo, M Rono, W Injera, A Delong, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 64 (2), 220-224, 2013 | 28 | 2013 |
| Effects of political conflict induced treatment interruptions on HIV drug resistance M Mann, MN Lurie, S Kimaiyo, R Kantor AIDS reviews 15 (1), 15, 2013 | 26 | 2013 |
| Projection of costs of polio eradication compared to permanent control M Zimmermann, B Hagedorn, H Lyons The Journal of Infectious Diseases 221 (4), 561-565, 2020 | 22 | 2020 |
| Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: a cost-effectiveness analysis M Zimmermann, K Frey, B Hagedorn, AJ Oteri, A Yahya, M Hamisu, ... Vaccine 37 (41), 6039-6047, 2019 | 22 | 2019 |
| HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1–Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077 R Kantor, D Bettendorf, RJ Bosch, M Mann, D Katzenstein, S Cu-Uvin, ... PLoS One 9 (4), e93537, 2014 | 17 | 2014 |
| Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya MR Zimmermann, E Vodicka, JB Babigumira, T Okech, N Mugo, S Sakr, ... Cost Effectiveness and Resource Allocation 15, 1-10, 2017 | 16 | 2017 |
| Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in namibia: a cost–utility analysis M Mann, A Mengistu, J Gaeseb, E Sagwa, G Mazibuko, JB Babigumira, ... Drug safety 39, 859-872, 2016 | 14 | 2016 |
| Capacity building and predictors of success for HIV‐1 drug resistance testing in the Asia‐Pacific region and Africa S Land, J Zhou, P Cunningham, AH Sohn, T Singtoroj, D Katzenstein, ... African Journal of Reproduction and Gynaecological Endoscopy 16 (1), 2013 | 14 | 2013 |
| Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies E Vodicka, M Zimmermann, AL Lopez, MW Silva, L Gorgolon, T Kohei, ... Vaccine 38 (13), 2833-2840, 2020 | 12 | 2020 |
| Household costs of diarrhea by etiology in 7 countries, the global enterics mulitcenter study (GEMS) M Zimmermann, K Kotloff, D Nasrin, A Roose, MM Levine, R Rheingans, ... Open forum infectious diseases 6 (4), ofz150, 2019 | 10 | 2019 |
| Exploring the cost effectiveness of shared decision making for choosing between disease-modifying drugs for relapsing-remitting multiple sclerosis in The Netherlands: a state … IEH Kremer, M Hiligsmann, J Carlson, M Zimmermann, PJ Jongen, ... Medical Decision Making 40 (8), 1003-1019, 2020 | 9 | 2020 |
